Status and phase
Conditions
Treatments
About
This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)
Full description
After treatment subjects will be observed for up to 1 year.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Note: France will only enroll patients in Cohort 2.
Key Exclusion Criteria:
Subjects may receive supportive therapies to meet the above criteria
Primary purpose
Allocation
Interventional model
Masking
31 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal